Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection.

Document Type

Article

Publication Date

4-1-2019

Publication Title

Expert opinion on investigational drugs

Keywords

ACX-362F; CRS3123; DS-2969b; LFF571; MCB3681/MCB3837; RBX 2660; ribaxamase; ridinilazole

Abstract

INTRODUCTION: Clostridioides (Clostridium) difficile Infection (CDI) is an urgent global threat causing ~500,000 infections annually in the United States of America (USA) and is associated with a 36% 30-day attributable mortality rate. Despite the availability of three therapeutic agents, CDI recurrence occurs in 20-40% of patients, with a 30-40% second recurrence rate in these patients. Consequently, there is a need for novel agents for treating CDI. Areas covered: We searched MEDLINE, PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for agents in early stages of clinical development. These drugs include ACX-362E, DS-2969b, LFF 571, RBX2660, ribaxamase, ridinilazole that have advanced to at least phase 2 and several other drugs in phase 1 development. Expert opinion: The challenge for these new agents is three-fold: (1) to have a novel approach such as a different target/mechanism of action; (2) be 'significantly' better than existing agents in regard to 'sustained clinical response'; or (3) be priced at a reasonable cost when it comes to market or perhaps all three. Their utility can only be proven by clinical trials.

Department

Pharmacy

Link to Full Text

PSJH Full Text

Share

COinS